Glenmark Generics (Glenmark), a subsidiary of Glenmark Pharmaceuticals, has entered into a settlement and license agreement with Nycomed US to resolve the patent infringement lawsuit regarding Glenmark’s ANDA for fluticasone propionate 0.05 per cent, lotion, currently marketed by Nycomed US as Cutivate.

Under the terms of the settlement agreement, Glenmark will be able to market and distribute its fluticasone propionate lotion under a royalty-bearing license from Nycomed US in March 2012, or earlier in certain circumstances. Glenmark believes that it is entitled to 180 days of exclusivity with respect to its fluticasone propionate lotion, as the first generic company to file an ANDA for the product.

Cutivate (fluticasone propionate) 0.05 per cent lotion had annual sales of approximately USD 48 million in the United States, based on IMS Health sales data ending December 2010.